Literature DB >> 3941290

Alterations in penicillin-binding proteins of clinical and laboratory isolates of pathogenic Streptococcus pneumoniae with low levels of penicillin resistance.

S Handwerger, A Tomasz.   

Abstract

Several recent surveys of clinical isolates have indicated that substantial fractions of naturally occurring populations of Streptococcus pneumoniae have undergone a distinct upward move in the required minimal inhibitory concentration (MIC) of benzylpenicillin (from a range of 0.006-0.008 to 0.03-0.05 microgram/ml). Evidence is presented that in clinical pneumococcal isolates, penicillin-binding proteins (PBPs) groups 1 and 2 have a decreased affinity for radioactive benzylpenicillin as compared with penicillin-sensitive isolates from the same locale. Exposure of a penicillin-sensitive type 2 strain (MIC, 0.006 microgram/ml) to sequentially increasing concentrations of penicillin allowed the isolation of spontaneous resistant mutants with stepwise increases in the MIC of penicillin required (0.01-0.02, 0.025-0.05, and 0.1 microgram/ml), and in these laboratory isolates too, PBP groups 1 and 2 showed decreased affinity for labeled benzylpenicillin. DNA from the low-level resistant clinical or laboratory isolates could be used to transform the appropriate levels of penicillin resistance into penicillin-sensitive laboratory isolates. These findings suggest that significant fractions of natural pneumococcal populations may have acquired one or two of the low-level penicillin resistance genes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941290     DOI: 10.1093/infdis/153.1.83

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network.

Authors:  A E Simor; M Louie; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci.

Authors:  Z Markiewicz; A Tomasz
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

3.  In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.

Authors:  K V Singh; T M Coque; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Alterations in kinetic properties of penicillin-binding proteins of penicillin-resistant Streptococcus pneumoniae.

Authors:  S Handwerger; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

Review 5.  Modification of penicillin-binding proteins as mechanisms of beta-lactam resistance.

Authors:  F Malouin; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

Review 6.  World-wide development of antibiotic resistance in pneumococci.

Authors:  P C Appelbaum
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

7.  A mutation in the D,D-carboxypeptidase penicillin-binding protein 3 of Streptococcus pneumoniae contributes to cefotaxime resistance of the laboratory mutant C604.

Authors:  J Krauss; R Hakenbeck
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

8.  Serotypes and resistance patterns of Streptococcus pneumoniae causing systemic disease in northern Norway.

Authors:  T Magnus; B M Andersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

9.  Beta-lactam-specific resistant mutants of Staphylococcus aureus.

Authors:  E Tonin; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

10.  Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the beta-lactam binding site.

Authors:  R Hakenbeck; H Ellerbrok; T Briese; S Handwerger; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.